Regulus Therapeutics, Inc. (NASDAQ:RGLS) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Joseph Hagan - President & CEO Conference Call Participants Yi Chen - H.C. Wainwright & Co. Operator Good morning, and welcome to the Regulus Therapeutics Second Quarter Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator instr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35670 Regulus Therapeutics Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporat ...

Regulus Therapeutics, Inc. (NASDAQ:RGLS) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Joseph Hagan - President, CEO & Director Conference Call Participants Yi Chen - H.C. Wainwright & Co. Operator Good day, and welcome to the Regulus Therapeutics Inc. First Quarter 2022 Conference Call. [Operator Instructions]. Please note, this event is being recorded. I would now like to turn the conference over to Cris Calsada, Chief Financial Officer. Please go ahe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) 4224 Campus Point Court, Suite 210 92121 San Diego CA FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION ...

Regulus Therapeutics Inc. (NASDAQ:RGLS) Q4 2022 Earnings Conference Call March 10, 2022 5:00 PM ET Company Participants Cris Calsada - Chief Financial Officer Jay Hagan - President and Chief Executive Officer Denis Drygin - Chief Scientific Officer Conference Call Participants Brian Cheng - Cantor Fitzgerald Yi Chen - H.C. Wainwright Operator Ladies and gentlemen thank you for standing by and welcome to the Regulus Therapeutics Q4 2021 Conference Call. [Operator Instructions] I’d now like to turn the confer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35670 Regulus Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-4738379 (State ...

Regulus Therapeutics Inc. (NASDAQ:RGLS) Q3 2021 Earnings Conference Call November 10, 2021 5:00 PM ET Company Participants Cris Calsada - Chief Financial Officer Jay Hagan - President and Chief Executive Officer Denis Drygin - Chief Scientific Officer Conference Call Participants Brian Cheng - Cantor Fitzgerald Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the Regulus Therapeutics Inc. Quarter 3 2021 Conference Call. [Operator Instructions] As a reminder, this confer ...

or UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35670 Regulus Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-4738379 (State or Other J ...

REGULUS Corporate Presentation August 2021 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to undertake certain activities and accomplish certain goals with respect to development, regulatory and other activities related to the RGLS4326 program in ADPKD, including the p ...

Regulus Therapeutics Inc. (NASDAQ:RGLS) Q2 2021 Earnings Conference Call August 10, 2021 5:00 PM ET Company Participants Cris Calsada – Chief Financial Officer Jay Hagan – President and Chief Executive Officer Denis Drygin – Chief Scientific Officer Conference Call Participants Yanan Zhu – Wells Fargo Securities. Andreas Argyrides – Wedbush Securities Yi Chen – H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by and welcome to the Regulus Therapeutics Second Quarter 2021 Financial Resul ...